Demser (metyrosine) NDC 25010-305

NDC codes

FDA NDC Directory

Product NDC (as listed)25010-305Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25010-0305Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
25010-305-15	25010030515	100 CAPSULE in 1 BOTTLE (25010-305-15)Marketed from Oct 3, 1979

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Demser
Generic name (nonproprietary): metyrosine
Active ingredients: Metyrosine — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Bausch Health US, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 017871
Marketing start: Oct 3, 1979
Listing expires: Dec 31, 2026
Other FDA classes: Catecholamine Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 25010-305_7997d826-eb49-4688-9833-e668985c1e74SPL ID 7997d826-eb49-4688-9833-e668985c1e74SPL set ID 32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92RxCUI 197980, 201388UNII DOQ0J0TPF7
Pharmacologic class: Catecholamine Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N425010030515 followed by a unit qualifier and the quantity

Package 25010-0305-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 1, 2021.

Indications (excerpt from the label)

INDICATIONS AND USAGE DEMSER is indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery 2. Management of patients when surgery is contraindicated 3. Chronic treatment of patients with malignant pheochromocytoma DEMSER is not recommended for the control of essential hypertension.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 017871

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 017871
Product	Strength	Form · route	Labeler	Product NDC
Metyrosine	Metyrosine 250 mg/1	CapsuleOral	Oceanside Pharmaceuticals	68682-310